Welcome to our dedicated page for Kala Pharmaceuticals news (Ticker: KALA), a resource for investors and traders seeking the latest updates and insights on Kala Pharmaceuticals stock.
KALA BIO, Inc. develops a dual strategy that combines a clinical-stage biologics pipeline for rare and severe eye diseases with an on-premises artificial intelligence infrastructure platform for biotechnology and pharmaceutical clients. Company updates cover the MSC-S platform, the KPI-012 clinical program, Researgency.ai, and the Bionic Intelligence Research Agent for secure research, clinical, regulatory, and data-workflow applications.
News also addresses capital-structure actions and corporate-status developments, including registered equity offerings, debt settlement, Nasdaq listing matters, governance changes, and the completed 1-for-50 reverse stock split of KALA common stock.
KALA BIO (NASDAQ: KALA) announced a 1-for-50 reverse stock split, effective 4:05 p.m. ET on May 8, 2026. Common stock will trade on a split-adjusted basis beginning at market open on May 11, 2026, under the symbol KALA. The new CUSIP is 483119301.
Outstanding shares will be reduced from 929,491,578 to approximately 18,589,832. Fractional shares will be paid in cash based on the Nasdaq closing price on May 7, 2026. Equity awards, warrants and convertible securities will be proportionally adjusted.
KALA BIO (NASDAQ: KALA) hailed a U.S. Executive Order signed April 18, 2026 that directs FDA priority review of psychedelics, asks DEA to reduce research restrictions, creates expanded Right-to-Try access, and allocates $50 million to accelerate psychedelic therapy research.
KALA says the policy materially strengthens the regulatory and commercial outlook for its client Red Light Holland and increases commercial relevance for KALA’s Researgency.ai agentic AI platform, which Red Light engaged on March 18, 2026.
Kala Bio (NASDAQ: KALA) engaged Dr. Saeid Babaei as Senior Scientific Advisor on April 1, 2026 to evaluate clinical and molecular assets, including its MSC Secretome platform, using AI-enabled analytics, digital health tools, and secure data integration to assess responder hypotheses and amended indication opportunities.
The initial work will review Phase 2 datasets, trial protocols, and translational hypotheses to inform development, partnering, licensing, or commercialization pathways.
KALA BIO (NASDAQ: KALA) announced the commercial launch of the Bionic Intelligence Research Agent (BIRA) on March 30, 2026, delivered via the Researgency.ai platform under an exclusive worldwide license with Younet. BIRA runs a 70-billion-parameter model for biotech and pharma research inside VPN-only, client-controlled infrastructure.
The platform targets enterprise security, audit trails, private data sovereignty, and a platform-as-a-service revenue model, and Kala highlighted a near-term roadmap of four agentic features including alerts, IP monitoring, and compressed publication reviews.
Red Light Holland (CSE: TRIP; FSE: 4YX; OTCQB: TRUFF) engaged Kala Bio's Researgency.ai platform to support clinical development of PEX010, Filament’s patented botanical psilocybin drug candidate. The engagement will deploy agentic AI for clinical planning, protocol optimization and scenario modeling as Red Light advances PEX010 following a definitive arrangement to acquire Filament.
PEX010 is supplied to >70 clinical sites, has Health Canada and FDA trial authorizations, and showed positive Phase 2 data in alcohol use disorder; Kala holds exclusive worldwide distribution/development license for Researgency.ai.
Kala Bio (NASDAQ: KALA) rebranded Researgency.ai and says its enterprise AI platform is live, with the company expecting to ship its first commercial AI agent in approximately 14 days. The firm positions Researgency.ai as a secure, auditable OS for biotech agents targeting research, trials, regulatory, safety, and commercial workflows.
Kala frames this move as a shift from a single-drug biotech to a dual-engine company combining an FDA-designated drug pipeline with a scalable AI product aimed at a projected $180+ billion AI-in-healthcare market by 2030.
KALA BIO (NASDAQ: KALA) announced a strategic initiative to deploy an on-premises, data-sovereign AI infrastructure for biotech and an exclusive license to the proprietary Researgency platform for an initial 12-month term.
The platform will be first applied internally to KALA’s MSC-S datasets and KPI-012 program, with external licensing planned after internal validation.
KALA BIO (NASDAQ:KALA) announced it has completed a loan settlement with Oxford Finance, resolving approximately $10.6 million of debt as of December 26, 2025. The company made a $2.0 million payment required under a November 25, 2025 Loan Settlement Agreement, which fully satisfied obligations under the Settlement Agreement and the underlying May 4, 2021 Loan Agreement.
Management said the settlement removes a material overhang and increases strategic flexibility. Separately, on December 30, 2025, the board approved inducement grants totaling 400,000 common shares to four new employees.
KALA BIO (NASDAQ:KALA) closed a registered direct offering on Dec 5, 2025, selling 10,000,000 shares (or pre-funded warrants) at $1.00 per share, generating approximately $10 million in gross proceeds before fees.
The offering was priced at-the-market under Nasdaq rules, used a shelf registration (File No. 333-270263 declared effective May 11, 2023), and named H.C. Wainwright & Co. as exclusive placement agent. The company intends to use net proceeds to repay certain indebtedness and for general corporate purposes. Prospectus materials are available on the SEC website.
KALA BIO (NASDAQ:KALA) entered definitive agreements for a registered direct offering of 10,000,000 shares (or pre-funded warrants) at $1.00 per share, expected to close on or about December 5, 2025. Gross proceeds are expected to be approximately $10 million before placement agent fees and offering expenses. H.C. Wainwright & Co. is the exclusive placement agent. The company intends to use net proceeds to repay certain indebtedness and for general corporate purposes. The securities are offered under a shelf registration (File No. 333-270263) declared effective May 11, 2023; offering materials will be filed with the SEC and available on the SEC website.